Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Survodutide Timeline Boehringer Ingelheims SYNCHRONIZE program includes multiple Phase 3 trials: SYNCHRONIZE-1: Obesity without type 2 diabetes (726 participants, 76 weeks) SYNCHRONIZE-2: Obesity with type 2 diabetes (755 participants, 76 weeks) SYNCHRONIZE-CVOT: Cardiovascular outcomes (4,935 participants target) LIVERAGE trials: MASH-specific studies initiated October 2024 FDA Breakthrough Therapy designation for MASH may accelerate review for that indication specifically
Questions remain but this is nonetheless very encouraging, said Nora Volkow, a study co-author and director of the National Institute on Drug Abuse, in the National Institutes of Health press release
10.1046/j.1365-313X.2003.01715.x 103 PolleA
Whether youre out for the day or just need something quick and easy, these disposables have got your back
JAMA 2022;327:1963-73.ArticlePubMedPMC 18
US$ 27.38
US$ 25.55
US$ 22.51
US$ 28.60
US$ 26.98
US$ 24.48
US$ 26.42
US$ 28.72
US$ 22.18
US$ 23.01
